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Abstract  
Oxytocin (OT) is a small neuropeptide, which is present in human plasma at extremely low 
endogenous levels of only a few pg/ml.  It is mainly involved during labour and lactation but it 
has recently also been found that OT  is involved in social behaviours like bonding and feeling 
empathy. During the last couple of years, the interest in OT has been raised and due to the 
matrix complexity, it is very challenging to develop a highly sensitive assay to be able to 
measure endogenous OT. An established quantitative tool for the detection of peptides in 
biological samples is liquid chromatography (LC) combined with tandem mass spectrometry 
(MS/MS). However, when working with complex matrices and concentrations in the low 
pg/ml range, an efficient sample preparation is required to remove endogenous matrice 
components which interfere with the detection of the analyte by LC-MS/MS analysis. In this 
project the potential of using immunocapture as sample preparation was investigated. The 
immunocapture techniques investigated where Dynabeads® and MSIATM pipette tips. To 
evaluate the success of the developed immunocapture technique a SPE method for OT, used 
for comparison, was optimized. Using commercially available antibodies, the Dynabeads® 
showed a great potential whereas the results for MSIATM were inconclusive. The Millipore 
antibody MAB5296 used together with Dynabeads® Protein G was found to generate the 
highest recovery. To increase the recovery during optimization of the immunocapture 
method, parameters like elution, incubation time and sample volume were investigated. It 
was found that these parameters did not have a great impact on recovery but an increase in 
sample volume, without changing the eluate volume, did generate approximately a twofold 
increase in signal, making it possible to obtain a LLOQ of 10 pg/ml. The final immunocapture 
method showed a good linearity in the concentration range of 10 to 100 pg/ml using seven 
calibration points. The precision and accuracy were qualified using four quality control (QC) 
samples (10, 30, 45 and 85 pg/ml). The precision ranged from 12 to 15% and the accuracy 
ranged from -8 to 2% except for the HIGH QC-sample where it ranged from +23 to 33%. This 
was probably due to the use of wrongly spiked QC-samples (100 pg/ml). When comparing the 
final method with the SPE it was found that a much cleaner extract was obtained with the 
immunocapture method where endogenous OT was detected whereas no endogenous OT 
could be seen when using SPE. The S/N for 5 and 10 pg OT/ml plasma was 4.01 and 0.97 for 
the SPE prepared samples compared to 25.3 and 41.4 for the immunocapture method. These 
observations show that immunocapture is an efficient technique for selective extraction of a 
target peptide enabling LC-MS/MS detection at very low concentrations in complex matrices 
such as plasma. 
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Abbreviations 
Ar: Argon 
BSA: Bovine serum albumin 
EIA: enzyme immunoassay 
ELISA: enzyme-linked immunosorbent assay 
ESI: Electrospray ionization 
Fc-region: Fragment crystallisable region 
Ig: Immunoglobulins 
IS: Internal Standard 
LC-MS/MS: Liquid chromatography-tandem mass spectrometry 
LLOQ: lower limit of quantification  
m/z: mass-to-charge ratio 
MRM: multiple reaction monitoring 
MSIATM: Mass Spectrometric Immunoassay 
N2: nitrogen gas 
OT: Oxytocin 
PBS: Phosphate buffered saline 
QC: quality control 
RIA: radioimmunoassay 
S/N: signal-to-noise ratio 
SPE: Solid Phase Extraction 
TFA: Trifluoroacetic acid 
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1. Introduction  
Oxytocin (OT) is a biologically significant neuropeptide, which is mainly involved during 
labour and lactation. Recently, it has also been found that OT is involved in several social 
behaviours like bonding and increasing trust and empathy in human. In addition, a possible 
link between OT and neurological disorders is being investigated (Zhang et al., 2011). 
Oxytocin is present in human plasma at extremely low endogenous levels of only a few pg/ml. 
Since 2004 there are several commercially available methods for measuring OT including 
ELISA, EIA and RIA. Unfortunately, evaluation of these methods has shown a lack of reliability 
and specificity (McCullough et al., 2013). Due to the matrix complexity, it is very challenging 
to develop a highly sensitive assay to be able to measure endogenous OT. Liquid 
chromatography (LC) with tandem mass spectrometry (MS/MS) detection is an established 
quantitative tool for peptides in biological samples with high selectivity and sensitivity in 
detection. However, for the determination of peptides at low pg/ml levels in plasma samples, 
several studies have stressed the need for (1) efficient sample preparation techniques to 
provide a clean sample extract for analysis and (2) selective LC analysis using coupled 
columns with orthogonal  separation capability, in order to establish a sensitive and robust 
method (Szapacs & Kellie, 2014) (Bylda et al., 2014).   
Immunocapture has proven to be an efficient sample clean-up technique for the analysis of 
proteins and peptides in biological samples using LC-MS/MS. The immunocapture can be 
performed both as off-line sample preparation and on-line in a coupled column LC system 
(Winther et al., 2009).  The goal of this project is to investigate the potential of off-line 
immunocapture techniques for efficient sample purification of oxytocin from human plasma 
to prepare a clean extract for LC-MS/MS analysis.  
1.1.Problem formulation 
In the pharmaceutical industry the use of lower doses of potent peptide drugs is becoming 
more and more interesting. Thus, this places higher demands on sensitive quantitative assays 
to measure peptides at low pg/ml or even lower levels which in turn requires efficient sample 
preparation when working with complex matrices such as plasma. This project focuses on 
developing a sensitive assay for the quantification of OT with aims of implementing a 
successful method on the company’s own peptide drugs.   
1.2. Aim  
The aim of this project is to: 
 explore different possibilities for the purification of OT  from plasma samples using the 
off-line immunocapture techniques; magnetic beads and pre-coated pipette tips.  
 explore different coating techniques in order to optimize the immunocapture process. 
 develop a quantitative assay for the quantification of OT  in human plasma samples 
with high sensitivity using LC-MS/MS. 
Nevin Belul 
June 2015 
8 
 
2. Theory 
2.1. Bioanalysis in the pharmaceutical industry 
Bioanalysis is the measurement of drug concentrations in biological matrices such as serum, 
plasma, blood, urine, saliva and tissue. In the pharmaceutical industry, bioanalysis is 
conducted to support the development of new drugs and drug formulations. 
Plasma and serum are the two most common bio-specimens for bioanalysis. The 
measurement of low abundance drugs in plasma is a difficult and challenging task as plasma 
contains endogenous lipids, peptides and proteins of a large dynamic range. Therefore,  
efficient sample preparation procedures are required to extract the target molecule from the 
biological matrix of interest before the measurement with a sensitive instrument, like LC-
MS/MS, can be performed for large sample series using a robust method (Hansen & Pedersen-
Bjergaard, 2015). 
For bioanalysis of therapeutic peptides present at low pg/mL concentrations in plasma, the 
complex matrice makes the identification and quantification highly challenging.. A successful 
bioanalysis procedure require selective isolation of the target peptide (Hansen & Pedersen-
Bjergaard, 2015). 
2.1.1. Matrix Effects 
To describe the problems encountered during analysis of complex biological samples, such as 
plasma, with variation in ionization efficiency and thus on the signal provided by the MS 
detector, the term matrix effects is used. Matrix effects can be caused by both endogenous and 
exogenous compounds eluting in the LC separation with the same retention time as the target 
analyte. Endogenous compounds causing interference could be metabolites of the target 
analyte, lipids, peptides or proteins. The exogenous compounds are all the substances 
introduced during sample preparation and analysis. Studies have shown that the most 
important interferents are phospholipids. These polar lipids are very difficult to remove from 
the biological samples. Phospholipids are very abundant in serum and plasma since they are 
major constituents of cell membranes. Phospholipids consist of two functional groups, a 
hydrophilic head made up of choline and phosphate units, and a hydrophobic tail composed of 
fatty acyl chains. These two functional groups cause ion suppression effects during LC-MS/MS 
analysis especially when using electrospray ionisation (Bylda C. et al., 2014). 
Several approaches can be taken to reduce or eliminate matrix effects. One strategy is to 
optimize the chromatographic separation so that the target analyte and interfering 
compounds are separated in time but unfortunately this can result in very long run times. 
Another strategy is to instead optimize the sample preparation to obtain a clean extract of the 
target analyte. A proper sample preparation can eliminate or strongly reduce the matrix 
effects. 
Nevin Belul 
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2.1.1.1. Internal Standards 
An internal standard (IS) is used in a quantitative LC-MS/MS method to compensate for any 
variation caused during sample preparation, sample injection and the final LC-MS/MS 
detection. A good IS usually has a structure or physical/chemical properties similar to the 
analyte to be measured. Therefore stable isotope IS such as 2H, 13C and 15N-labeled analogues 
are the preferred IS. An internal standard is added in a constant concentration to the samples.  
A good IS should compensate for endogenous and exogenous differences between samples 
and sample handling reproducibility during the analysis procedure. The ratio of IS to given 
analyte concentration remains constant because the same fraction of each is lost during 
sample preparation and sample analysis (Harris D. C., 2010). However, a large variability in 
the IS response through a sample series (e.g. 96 samples) can cause concerns regarding the 
assay’s resilience to subtle changes in the matrix composition and may raise questions about 
the trueness of the results. A Standard Operating Procedure (SOP) describing the acceptance 
criteria of IS variation between prepared calibration and quality control samples  and real-life 
samples is common in regulatory bioanalysis (White et al., 2014)(Harris D. C., 2010).  
2.2. Oxytocin 
Oxytocin (OT) (Greek, “quick birth”) is a cyclic neuropeptide consisting of nine amino acids, 
which was isolated and synthesized biologically by Vincent du Vigneaud in 1953, a work 
awarded with the Nobel Prize in Chemistry year 1955 (peptidesciences.com). It is synthesized 
in the hypothalamus together with its carrier protein neurophysin I and transported axonally 
to the posterior pituitary gland, also called the neurohypophysis, where it is either secreted or 
stored. OT has both peripheral (hormonal) – and brain actions. It acts on smooth muscle cells 
causing for example uterine contractions and milk ejection in women (Bjålie et al., 1998) but 
it also acts within the brain where it is involved in e.g. social recognition and bonding in both 
men and female. The action of oxytocin is mediated by the oxytocin receptor which belongs to 
the class I G-protein coupled receptor family. It is a high-affinity receptor that requires both 
Mg2+ and cholesterol to function (Gimpl & Fahrenholz, 2001).  
2.2.1. Structure and  properties  
As mentioned, OT is a peptide consisting of nine amino acids with the molecular formula  
C43H66N12O12S2. See figure 1 for 2D & 3D-structure. OT has a molecular weight of 1007 Da and 
consists of the amino acids in the order of cysteine-tyrosine-isoleucine-glutamine-asparagine-
cysteine-proline-leucine-glycine-amine. The cysteine residues form a disulfide bond. The OT 
molecule is very similar to the vasopressin molecule, which retains water in the body and 
constrict blood vessels, and they are the only known hormones to act at a distance. The only 
difference between the two hormones is the two amino acids at residue 3 and 8.  
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OT is rapidly metabolized in the liver and in the plasma by oxytocinases. It is excreted 
unchanged in the urine and has a half-life of 6 minutes but this is decreased during lactation 
and in late pregnancy. Other properties include a hydrophobicity of -2.7, meaning that the OT 
molecule is polar, and an isoelectric point of 5.51, meaning that the oxytocin molecule carries 
zero net electrical charge at pH 5.51 (DrugBank, 2014).  
2.3. Antibodies 
Antibodies, also known as immunoglobins (Ig) are Y-shaped glycoproteins with a molecular 
weight of approximately 150 kDa and are produced in response to an antigen. The antibody 
can recognize and bind to the antigen that caused its production. There are several Ig 
isotypes: IgG, IgA, IgM and IgD, where IgG is the most common one in human serum. The 
isotypes differ in molecular size, structure, charge, amino acid composition and carbohydrate 
content but all Ig have a basic structure composed of four polypeptide chains connected to 
each other by disulfide bonds, creating a Y-shape. The basic structure includes a constant 
region and  a variable region, where the antigen is recognized via the variable region. The 
antigen is recognised by the antibody through its epitope, which is the specific region on the 
antigen to which the antibody binds. There are both monoclonal and polyclonal antibodies. A 
monoclonal antibody recognizes one specific epitope of the antigen while a polyclonal 
antibody recognizes multiple epitopes on any one antigen. Monoclonal antibodies normally 
have a higher specificity toward its antigen while polyclonal antibodies may cause cross-
reactivity. Specific antibodies can be produced by immunization or artificially through 
hybridoma formation (Prescott et al., 2002).     
  
Figure 1. 2D (left) & 3D (right) - structure of OT (ChemSpider)(DrugBank, 2014). 
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2.4. Proposed Approach  
OT is an interesting peptide with low endogenous levels of a few pg/ml. Since it is of interest 
to determine OT in human plasma with high selectivity and with a limit of quantification 
below endogenous levels, a bioanalysis method will demand an efficient sample preparation 
procedure before analysis with LC-MS/MS. Plasma mostly contains water (90%) but also 
proteins (8%), mainly albumin (35-54 mg/ml), immunoglobins, and inorganic and organic 
ions (2%) dominated by sodium and chloride (Dugdale, 2013) (Hansen & Pedersen-Bjergaard, 
2015). These compounds cause major matrix effects during analysis and therefore a proper 
sample preparation is required.  
To purify OT from plasma, novel sample preparation methods like immunocapture techniques 
can be used. In this project, sample preparation with magnetic beads and pre-coated pipette 
tips will be studied. These techniques are both based on antibodies and antibody-antigen 
interactions. To evaluate the efficiency of the immunocapture sample preparation, the 
techniques will be compared not only to each other but also to solid phase extraction (SPE). 
SPE is the sample preparation technique used by the company -  prior to this project. The 
purified sample, containing the target analyte (OT) and an IS, will then be analysed using LC-
MS/MS. 
2.4.1. Dynabeads® Magnetic Separation Technology 
In year 1976 the Norwegian professor John Ugelstad achieved something that prior to this 
year only had been achieved by NASA in the weightless conditions of space. Professor 
Ugelstad succeeded in making spherical polystyrene beads of exactly the same size. These 
beads were later made magnetisable and in year 1982 the first commercially supermagnetic 
beads were developed. The Dynabeads® are today owned and produced by InvitrogenTM and 
Novex® – both a part of Thermo Fisher Scientific (Life Technologies). There are several types 
of Dynabeads® with varieties in size and surface functionalities, which gives these magnetic 
beads a wide application range. In this project four different types of Dynabeads® were 
evaluated. The Dynabeads® are used as a magnetic separation technology providing a 
consistent surface on which various bioreactive molecules e.g. antibodies, proteins, DNA/RNA 
probes can be adsorbed or coupled on. The beads are monosized, spherical and 
superparamagnetic, meaning that they only exhibit magnetic properties in a magnetic field 
leaving no residual magnetism once the field is removed. The magnetic material is encased in 
a thin polymer shell and is evenly dispersed in each bead providing a specific and defined 
surface for binding of e.g. an antibody. The full control of parameters such as bead size, 
surface area, iron content and magnetic mobility during production of the beads provides 
consistent physical and chemical properties which in turn secures reproducibility and quality 
of the results. Thanks to the strictly controlled production the same surface area for each 
experiment can be offered, leading to efficiency and a unique reproducibility of the results 
(Life Technologies, 2015).  
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2.4.1.1. Dynabeads® Protein G (novex®) 
Dynabeads® Protein G are 2.8 µm in size and have recombinant Protein G, with a size of 
approximately 17 kDa, covalently coupled to the bead surface. The Dynabeads® Protein G 
suspension contains PBS, pH 7.4 with 0.01% Tween®-20 and 0.09% sodium azide as 
preservative and should be stored in 2 to 8 degrees Celsius. The principal of sample 
purification using Dynabeads® Protein G can be seen in figure 2 (left figure). The beads have 
a binding capacity of approximately 8 µg human IgG per mg beads where the antibody, during 
incubation, binds to the beads via its Fc-region. The binding strength of Protein G to different 
species of antibodies and their subclasses can be seen in figure 2 (right figure).  When using a 
magnet the magnetic beads migrate towards the magnet and create a pellet allowing an easy 
removal of supernatant. The recombinant Protein G does not contain any albumin binding 
sites hence albumin is not co-purified during the process (Life Technologies Corporation, 
2011). 
 
2.4.1.2. Dynabeads® M-280 Sheep anti-Mouse IgG (novex®) 
Dynabeads® M-280 Sheep anti-Mouse IgG have the same size as Dynabeads® Protein G, i.e. 
2.8 µm, but instead of recombinant Protein G, affinity purified polyclonal sheep anti-mouse 
IgG is covalently coupled to the bead surface. The bead suspension contains 6-7 x 108 
beads/ml in PBS (pH 7.4) with 0.1% BSA and 0.02% sodium azide. The sheep anti-Mouse IgG 
works as a secondary antibody and bind both light and heavy chain to mouse IgG1, IgG2a and 
IgG2b with minimal cross reactivity to human IgG. These beads can be used with two different 
approaches, either a direct or an indirect approach. The indirect approach can be of benefit 
for example if the antibody concentrations is low or the antibody-antigen affinity is weak. If 
this approach is taken the primary antibody is first allowed to bind to the antigen prior to 
Figure 2. Principle of sample purification using Dynabeads® Protein G (left). Different species of Ig´s and their subclasses 
and their affinity for Protein G (right).  
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addition of the Dynabeads®. In this project however, the direct approach has been used 
meaning that the sample containing the antigen is incubated with the Dynabeads® already 
containing the primary antibody. This approach is preferred when the affinity of the primary 
antibody is high. The primary antibody can be covalently cross-linked to the secondary 
antibody on the beads but this may affect the binding capacity of the antibody (Life 
Technologies Corporation, 2012).   
2.4.1.3. Dynabeads® M-280 Streptavidin & MyOneTM Streptavidin T1 (InvitrogenTM) 
The Dynabeads® M-280 Streptavidin have a bead diameter of  2.8 µm compared to the 
MyOneTM Streptavidin beads that have a diameter of 1 µm. These two bead types have a 
monolayer of recombinant streptavidin coupled to its surface and have been further blocked 
with BSA. The advantage of this monolayer is that the majority of the biotin binding sites have 
been left sterically available for binding of e.g. biotinylated antibodies. The streptavidin-biotin 
interaction has a very high binding affinity allowing a direct and fast isolation of any 
biotinylated molecule. One mg of the Dynabeads® M-280 Streptavidin binds approximately 10 
µg biotinylated IgG while one mg of the Dynabeads® MyOneTM Streptavidin T1 bind double the 
amount, approximately 20 µg. The Dynabeads® MyOneTM Streptavidin T1 are as mentioned 
smaller in size and therefore have a slower sedimentation rate during incubation (Life 
Technologies) (Life Technologies Corporation, 2011).  
2.4.2. Mass Spectrometric Immunoassay (MSIATM) Pipette Tips 
Sample preparation using immunocapture can also be made possible by using the MSIATM 
Disposable Automation Research Tips (D.A.R.T’STM). A MSIATM pipette tip has a volume of 300 
µl and is embedded with a highly porous immunoaffinity column on which an antibody of 
choice is immobilized by following a straight forward protocol. The MSIA system is said to be 
highly effective due to the micro-fluidic immunoaffinity column which enhances 
antibody/antigen kinetics and increases signal-to-noise ratio by improving the specificity and 
reducing the background. The protein recovery and reproducibility is also said to be superior 
compared to bead-based methods. The procedure includes 3 main steps: loading of the 
affinity ligand, purification and elution of the target analyte. To reduce sample complexity, 
antibodies are immobilized on a proprietary microcolumn surface to purify target analytes. 
Biological samples, such as plasma, are directed through microfluidic channels to expose the 
target analyte to the antibody which captures the analyte with high selectivity and specificity. 
The purified target is then eluted from the microcolumn and ready for MS analysis. (Thermo 
Fisher Scientific Inc. , 2014).  
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The MSIA D.A.R.T’sTM can be used manually together with the Thermo Scientific Finnpipette 
Novus i Multichannel Electronic Pipettes (8 or 12 well sample processing) (figure 3) or 
automated at using the Thermo Scientific Versette Automated Liquid Handling Platform. The 
pipettes employ a repetitive cyclical pipetting motion with up to 999 aspirations in one cycle. 
This motion allows for coupling of antibody, sample purification and enrichment of the target 
analyte, elution as well as washing steps where the tips are rinsed.  There are different types 
of MSIA tips available depending on what kind of antibody coupling is preferred. In this 
project streptavidin MSIA-tips and protein G and A MSIA-tips have been evaluated (Thermo 
Fisher Scientific Inc., 2013).   
2.4.2.1. Protein G and A/G MSIATM-tips    
The protein G and A MSIATM-tips contain covalently immobilized recombinant Protein G and 
A/G respectively. The recombinant Protein G has a molecular weight of approximately 21,600 
Da and contains two Fc-binding domains that can interact immunoglobins. In order to reduce 
nonspecific binding the albumin and cell binding sites have been eliminated. The recombinant 
Protein A/G has a molecular weight of approximately 50,000 Da and contains four Fc-binding 
domain, two from Protein A and two from Protein G (Thermo Fisher Scientific Inc., 2012).   
 2.4.2.2. Streptavidin MSIATM-tips    
As mentioned before the streptavidin-biotin interaction has a very strong binding affinity and 
this complex is one of the strongest non-covalent interactions in biology. This interactions is 
taken advantage of when using the MSIA Streptavidin D.A.R.T’S together with a biotinylated 
antibody. The streptavidin immobilized onto the tips is a Thermo-Pierce affinity-purified, 
recombinant streptavidin, isolated from Streptomyces avidinii. Streptavidin has four potential 
biotin binding sites and less non-specific binding than avidin. The MSIA Streptavidin D.A.R.T’S 
can be used in either a forward or reverse approach. Figure 4 shows an illustration of the 
forward approach where the biotinylated antibody first is coupled to the micro-column and 
then used to capture the antigen from a biological sample. This allows for simultaneous 
purification and enrichment of the analyte and this is the approach chosen in this project. In 
Figure 3. Thermo Scientific Finnpipette Novus i Multichannel Electronic Pipettes (Thermo Fisher Scientific Inc., 2013) 
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the reverse approach the biotinylated antibody is first incubated together with the antigen 
prior to coupling on to the micro-column on the MSIA Streptavidin D.A.R.T’S (Thermo Fisher 
Scientific Inc., 2013). 
 
Figure 4. Overview of the forward MSIA Streptavidin approach (Thermo Fisher Scientific Inc., 2013). 
 
2.4.3. Solid Phase Extraction (SPE) 
Solid Phase Extraction (SPE) is a chromatographic technique that is used for sample 
preparation. Typically a cartridge like device is used. The cartridge contains chromatographic 
packing material which is used to chemically separate the compounds. The SPE purification 
reduces or eliminates matrix effects which is crucial when working with biological samples. 
The SPE enables a sensitive, selective and robust LC-MS/MS analysis and at the same time 
removes interference (Harris D. C., 2010). In this project Waters Oasis SPE products have 
been used to optimize a method for oxytocin, which in turn will be compared to the sample 
preparations using immunocapture. 
Phospholipids and lysophospholipids are key contributors to ion suppression during LC-
MS/MS and by using Oasis SPE they can successfully be removed. Waters have patented five 
SPE chemistries and introduced the first water-wettable – yet hydrophobic – polymeric 
sorbent. Two of these chemistries were optimized in the project; HLB – Hydrophilic-
Lipophilic-Balanced reversed phase and WCX – Mixed-Mode Weak Anion-eXchange reversed 
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Figure 5. Structure of HLB Copolymer (left)  and WCX (right) (Waters Corporation, 2011). 
phase. Reversed phase SPE separates the analyte based on its polarity (Waters Corporation, 
2011). The water-wettable Oasis sorbents holds great retention of polar compounds in 
addition to having a relative hydrophobic retention capacity that is three times higher than 
for traditional silica-based SPE-sorbents like C18. A high retention capacity means that more 
analytes are retained with less breakthrough which in turn improves the recovery and overall 
reproducibility. One advantage with the Water-wettable Oasis sorbents is that even if the 
sorbent bed runs dry during conditioning or sample loading the retention capacity is not 
effected, giving a more robust method. Further, the water-wettable sorbents have a great 
stability both at pH extremes and in a wide range of solvents. When working with traditional 
silica-based sorbents the long-term, batch to batch reproducibility may be compromised by 
e.g. hydrolytic instability at pH extremes. The Oasis sorbents have demonstrated a consistent 
long term, batch-to-batch reproducibility for over 15 years (Waters Corporation, 2011).       
Oasis HLB is made from a specific ratio of two monomers, the hydrophilic N-vinylpyrrolidone 
and the lipophilic divinylbenzene. The Oasis HLB enhances the retention of polar analytes and 
provides superior reversed-phase capacity thanks to a neutral polar ”hook”. All Oasis mixed-
mode sorbents are built upon this unique HLB copolymer, see figure 5 (left figure). The Oasis 
WCX holds all the advantages of Oasis HLB (figure 5). It was designed to provide sample 
preparation for strong bases and quaternary amines and employs both ion exchange and 
reversed phase (Waters Corporation, 2011).  
There are several Oasis formats that can be used; 96-well extraction plates, syringe barrel – or 
glass cartridges, on-line columns and µElution plates that enables elution volumes of clean 
extracts to be as low as 25uL. 
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2.4.4. Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) 
LC-MS/MS is a common analytical technique with a very high sensitivity and selectivity and it 
is used in many application areas especially for quantitative analysis, one of them being 
bioanalysis of peptides. LC-MS/MS combines the capabilities of two different techniques, the 
separation capability of LC and the detection capability of MS/MS. MS is commonly used as a 
detector when working with chromatography and can provide both quantitative and 
qualitative information (Harris, 2010).  
2.4.4.1. Liquid Chromatography  
To be able to analyze a certain analyte, in a sample containing hundreds of other compounds 
in varying concentrations in 10-fold scale, effective separation prior to detection is required. 
Liquid chromatography is a chromatographic separation technique which involves two 
phases, a mobile phase and a stationary phase that move relative to each other. The sample to 
be analyzed is forced by a liquid at high pressure (mobile phase) through a closed column 
containing fine particles (stationary phase) which in turn enables a high resolution 
separation. The separation of the components of the sample is due to their different degrees 
of interaction with the stationary phase. The interactions between the sample components 
and the stationary phase is highly influenced by the composition and temperature of the 
mobile phase. The mobile phase typically consists of water/organic solvents (like acetonitrile 
or methanol) mixtures. Acetonitrile is typically the first choice since it has a low viscosity, 
which allows a low operating pressure and permits ultraviolet detection down to 190 nm. At 
this low level many analytes have some absorbance. It is also common that the mobile phase 
contains acids like TFA to assist in the separation (Harris, 2010) and avoid peak distortion 
due to interaction between basic groups in the analyte and the Si surface of the stationary 
phase of the column.  
The LC-system enables purification of the sample on-line and consists of an autosampler, a 
solvent delivery system (pumps), a sample injection valve and a high pressure 
chromatography column. The LC-system is then coupled to a MS/MS instrument as a detector, 
giving the powerful analytical tool LC-MS/MS. There are several types of columns that can be 
used. However, when working with MS/MS is it most common to use a column with a 
diameter of 2.1 mm since the typical interface of the MS/MS instrument i.e. electrospray 
ionization (ESI) requires low mobile phase flow < 1 ml. Other advantages with a narrow 
column is that lower use of mobile phase solvents is needed. The column contains the 
stationary phase which typically consist of microporous spherical, silica particles with 
diameters of 1.5-5 µm. The column temperature effects the efficiency regarding to mass 
transfer between the two phases and an elevated temperature enables a high-speed 
chromatography (Harris, 2010).  
The stationary phase can either be polar (e.g. silica surface) or nonpolar (coated with a 
bonded phase of e.g. carbon chains such as C4, C8 or C18). The solvent molecules compete with 
solute molecules for sites on the stationary phase and when solvent displaces solute from the 
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phase, elution occurs. A chromatogram is a graph that shows the detector response as a 
function of elution time. Depending on the identity of each compound in the sample, they will 
have different elution times and correspond to different peaks in a chromatogram. The time 
that elapses between injection of the mixture onto the column and the arrival of that 
compound to the detector is called retention time, tr. Using the same chromatographic 
conditions for each sample injection the tr should be identical for the analyte of interest and 
provides a mean for identification. The chromatographic separation should be optimized so 
that the peak for the target analyte is selective separated from other compounds in the 
sample. 
For very complex samples and in bioanalysis of low concentrations analytes, coupled column 
chromatography can be used to increase the selectivity of the chromatographic separation. 
Typically, the sample is injected on column no 1 and a fraction containing the analyte of 
interest and IS eluting from column no 1 is transferred to a trap column (column no 2) by 
valve switching of the LC-flow (heart-cutting). By using additional LC solvent pumps, the 
analyte and its IS is eluted off the trap column into a third analytical column for the final 
separation. By using  columns with different stationary phases, orthogonal chromatography,  
highly selective on-line separation can be obtained for complex samples. 
2.4.4.2. Tandem Mass Spectrometry (MS/MS) 
Mass spectrometry (MS) is a technique used for studying the masses of atoms or molecules or 
fragments of molecules. The principle of the technique is that gaseous species are ionized in a 
ion source and the formed ions are then accelerated by an electric field and separated in a 
mass analyzer according to their mass-to-charge ratio, m/z. The separated ions are detected 
by a ion counting device (e.g. electron multiplier). In a mass spectrum graph the detection 
response versus the m/z value is shown. The area of each peak is proportional to the 
abundance of each isotope. The MS used as a detector can be highly selective for the analyte in 
focus and this increases the signal-to-noise ratio (Harris D. C., 2010).  
The ion separation of gaseous ions in a MS instrument requires high vacuum. When solvent 
vaporizes, in the interface between the column in the LC-system and the mass spectrometer, a 
huge volume of gas is created. The majority of this gas must be removed before the ion 
separation in the mass spectrometer can take place. One way of introducing liquid from the LC 
into the MS is by using a method called electrospray ionization (ESI; nobel prize John Fenn, 
2002). An electrospray is used to produce ions by applying high voltage to a liquid to create 
an aerosol. Liquid from the LC-column enters a steel nebulizer capillary along with a coaxial 
flow of an inert gas such as nitrogen. When working with positive ion mass spectrometry the 
spray chamber is held at approximately – 3500 V. Together with the coaxial flow of nitrogen 
gas, a strong electric field at the nebulizer outlet creates a fine aerosol of charged particles. 
The ions from the aerosol are attracted toward a small orifice such as a capillary leading into 
the mass spectrometer by a strong potential (Harris D. C., 2010).   
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A tandem mass spectrometry consists of two mass analyzers and a collision cell between the 
mass analyzers. In a triple quadrupole MS/MS instrument the first mass analyzer is named 
Q1, the second, functioning as a collision cell, is named Q2 and the third mass analyzer is 
named Q3. Detection by multiple reaction monitoring (MRM) using a triple quadrupole mass 
spectrometer is a powerful method for quantifying target peptides. In the first step a mixture 
of ions from the electrospray ionization, enters quadrupole Q1. Only one selected precursor 
ion (the ion of interest) is then passed to the collision cell – quadrupole Q2. Q2 is a 
pressurized collision cell and this is where the precursor ion collides with a neutral gas, like 
N2 or Ar, and breaks into fragments called product ions. In quadrupole Q3 only a small 
number of specific product ions are selected to reach the detector. MRM is highly selective for 
the analyte of interest enhancing the lower detection limit for peptides by improving the 
signal-to-noise in detection compared to full scan MS analysis. See figure 6 for an overview.    
 
  
Figure 6. Principle of multiple reaction monitoring (MRM) using a triple quadrupole mass spectrometer. 
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3. Materials and Methods 
3.1. Chemicals and reagents  
The chemicals used for preparation of buffers required for the peptide purification and LC-
MS/MS were ammonium formate (NH₄COOH) (Sigma Aldrich), ammonia solution (25%; 
NH4OH)(Merck) acetonitrile hypergrade for LC-MS/MS (C2H3N) (Merck), formic acid (98-
100%; CH2O2) (Merck), methanol hypergrade for LC-MS/MS (CH4O) (Merck), acetic acid 
(100%; (C2H4O2) (Merck), trifluoroacetic acid (C2HF3O2) (Merck), potassium chloride (KCl), 
sodium chloride (NaCl) (Merck), glycine (C2H5NO2) (Sigma Aldric), citric acid (C6H8O7) (Sigma 
Aldrich), phosphoric acid (H3PO4), isopropyl alcohol (C3H8O)(iPrOH) and 
ethylenediaminetetraacetic acid (EDTA) (Sigma Aldrich).      
3.2. Equipment 
HulaMixer® Sample Mixer (Life Technologies), Allegra X-15R Centrifuge (Beckman Coulter), 
Sorvall RC-4 (Thermo Scientific),  VMS-C4 Advanced (VWR), PHM220 LAB pH Meter 
(MeterLab®), API 5000 (Applied biosystems), Xevo TQ-S (Waters) LC-20AD UFLC (Shimadzu), 
DHU-20A3 Degassr (Shimadzu), CTC Analytics HTS (Pal Systems), PB403-S (Mettler Toledo), 
MX5 Microbalance (Mettler Toledo), TurboVap®96 (Zymark), Vortex Maxi Mix II Type 37600 
Mixer (Thermolyne) and Positive Pressure-96 Processor (Waters).  
3.3. Preparation of standards and plasma samples 
Stock solutions of oxytocin and internal standard were prepared in 10mM ammonium 
formate pH 4.4. The internal standard used was oxytocin-d5. The stock solutions were 
prepared in concentrations of 1 mg/ml and stored in - 20°C. Care was taken to avoid excessive 
freeze-thaw cycles. The same stock solutions for OT and IS were used during the entire 
project. The stock solutions of OT were used to spike plasma samples for the immunocapture 
experiments. Plasma samples were spiked in various concentrations along with the 
experiments. The dilutions were done in plasma using serial dilution. The stock solutions 
were also used to spike controls in different concentrations. The controls were diluted in 
Acetonitrile: 0.01% BSA in 1% formic acid (20:80, v/v), using serial dilution, except for the 
last dilution were the elution buffer used for the specific experiment was used as dilution 
buffer. This was done to prevent unspecific binding of the OT or IS to the tube walls during the 
dilution steps. The plasma samples as well as the controls were stored in - 20°C in volumes of 
200 µl to avoid excessive freeze-thaw cycles. 
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3.4. LC-MS/MS 
Two different LC-MS/MS systems were used during the project. 
3.4.1. Triple quadrupole – API 5000  
The LC-MS/MS system consisted of a PAL HTS autoinjector, two Shimadzu LC-20AD pumps, a 
Shimadzu DGU-20A3 degasser and Applied Biosystems API 5000 triple quadrupole mass 
spectrometer. Data acquisition and processing were carried out using SCIEX Analyst® 
software version 1.4.2. The ESI source was operated in positive ionization mode and the 
MS/MS was set to monitor MRM transition m/z 1007.6 → m/z 723.60 for OT. The MS/MS 
operating conditions were as follow: Ion spray voltage 5500 V, collision energy 20.00 V,  
temperature 600°C,, ion source gas 1 20.00 and ion source gas 2 40.00.  
3.4.2. Triple quadrupole – Xevo TQ-S 
The LC-MS/MSsystem consisted of ACQUITY UPLC I-class system with XEVO TQ-S triple 
quadrupole mass spectrometer (all Waters). System control and data acquisition were 
performed with MassLynx® (Waters) version 4.1. The ESI source was operated in positive 
ionization mode and the MS/MS was set to monitor the two MRM transitions m/z 1007.6 → 
m/z 285.24 and m/z 1007.6 →  m/z 723.30 for OT. The optimized collision energy was 45 eV 
for the m/z 285.24 fragment and 28 eV for the m/z 723.30 fragment. The MS/MS operating 
conditions were as follows: nebuliser gas 7.0 bar, collision gas (Ar) 0.15 ml/min, cone gas (N2) 
150 l/h, desolvation gas (N2 ) 800 l/h, source temperature 150°C and desolvation 
temperature 500°C. 
3.5. Chromatographic conditions 
Two different LC configurations were used: A single LC column system was used with the API 
5000 system and a coupled column LC system was used with the Xevo TQ-S system.  
3.5.1. API 5000 system 
LC separation was performed with a Phenomenex Aeris Widepore, 3.6µm, XB-C18 column 
with column dimensions 50 mm x 2.1 mm. The mobile phases used were A: MQ-
water/acetonitrile 95/5 (v/v) with 0.2% formic acid and B: acetronitrile with 0.2% formic 
acid. The flow rate was set to 0.400 ml/min and the injection sample volume was 50 µl. The 
autosampler (Pal Systems) wash consisted of a weak wash with MQ-water/acetonitrile 90/10 
(v/v) and a strong wash with MQ-water/acetonitrile/acetone/iPrOH/formic acid 
240/250/250/250/10 (v/v). The gradient table can be seen in table 1.  
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Table 1. Gradient table. Solvent A: MQ-water/acetonitrile 95/5 (v/v) with 0.2% formic acid, solvent B: acetronitrile with 
0.2% formic acid. Column: Phenomenex Aeris.   
 Time (min) %A %B 
1. 0.20 96.5 3.5 
2. 0.60 89.5 10.5 
3. 0.90 84.6 15.4 
4. 2.70 58 42 
5. 2.72 58 42 
6. 2.75 0 100 
7. 4.00 0 100 
8. 4.10 96.5 3.5 
9. 6.00 Stop Stop 
 
3.5.2.  Xevo TQ-S system 
Chromatographic separation was carried out using a three-column coupled system. The 
columns used were BetaBasicTM (Thermo Scientific Fisher) CN, 5µm, with column dimensions 
50mm x 2.1mm, XBridgeTM (Waters ) C18, 10 m Direct Connect HP column with column 
dimensions 2.1 mm x 30mm (trap column) and ACQUITY (Waters) UPLC HSS T3 Column, 1.8 
µm with column dimension 2.1 mm X 50 mm. Since three columns were used, three binary 
pumps were used as well. The injection sample volume was set to 50 µL. The gradient tables 
for each pump can be seen in table 2-4. The column switching from the CN column to the trap 
column, i.e. a heartcut, was performed by valve switching between 1.10 and 1.60 min, 
directing the flow from the CN column to the trap column. Back flush of the CN-column was 
performed between 4.00 and 6.00 min while the gradient was running on the analytical 
column.  
Table 2. Gradient table – pump A. Solvent A: 0.05% TFA in MQ-water, solvent B: acetonitrile. Column: BetaBasicTM 
 Time (min) Flow Rate %A %B Curve 
1. Initial 0.300 82.5 17.5 Initial  
2. 2.20 0.300 82.5 17.5 6 
3. 2.50 0.300 20.0 80.0 11 
4. 3.90 0.300 20.0 80.0 11 
5. 4.00 0.300 82.5 17.5 11 
6. 7.00 0.300 82.5 17.5 11 
 
Table 3. Gradient table – pump B. Solvent A: 1mM ammonium formate pH 4.6, solvent B: acetonitrile. Column: XBridgeTM. 
 Time (min) Flow Rate %A % B Curve 
1. Initial 0.300 90.0 10.0 Initial  
2. 1.60 0.300 90.0 10.0 6 
3. 5.00 0.300 70.0 30.0 6 
4. 5.10 0.300 10.0 90.0 11 
5. 7.00 0.300 90.0 10.0 11 
6. 8.00 0.300 90.0 10.0 11 
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Table 4. Gradient table - pump C. Solvent A: 1 mM ammonium formate pH 6, solvent B: acetonitrile/MQ-water/formic acid 
70/28/2. Column: ACQUITY. 
 Time (min) Flow Rate %A %B Curve 
1. Initial 0.600 50.0 50.0 Initial  
 
Waters ACQUITY FTN autosampler was used for injection. Both a pre and post-inject wash of 
10 seconds respectively was applied using acetonitrile(methanol/isopropanol/MQ-
water/formic acid 25/25/24/24/1 (v/v/v/v).  
3.6. SPE 
SPE was carried out by using Oasis HLB and WCX 10 mg 96-well extraction plates. All resins 
were conditioned with 500 µl methanol and 500 µl Milli-Q water prior to use. Each step in the 
SPE procedure was carried out by loading the solution in the wells of the Oasis plate used. In 
order to press the liquids through the wells, the plate was placed on Waters Positive Pressure-
96 processor. Pressure was applied by manually increasing the pressure of the instrument. 
The flow-through fractions were collected using a deep-well plate and the flow-through 
fractions to be analysed were collected and saved in separate, clean deep-well plates. 
3.6.1. Determination of optimal SPE conditions 
Optimization of the SPE procedure was performed with both Oasis HLB (10 µg) 96-well plate 
and WCX (10 µg) 96-well plate to determine the optimal SPE plate for OT. The optimization is 
done to determine the optimal percentage of methanol and acetonitrile to be used in the SPE 
and also to determine whether the HLB or WCX plate should be used. The determination is 
done by analysing the extracts with LC-MS/MS (the Xevo TQ-system). 
15 ml pre-spiked human plasma with an OT concentration of 100 pg/ml was thawed and was 
together with 150 µL IS (100 ng/ml) diluted 1:1 with 4% H3PO4.. This gave a final 
concentration of 1000pg/ml IS in all samples. Further, 2 ml plasma, including 20 µl IS (100 
ng/ml) was diluted 1:1 with 4% H3PO4 as well, this was used as zero plasma (plasma with 
1000pg/ml IS but no OT added). Both plates were first conditioned with 500 µl methanol 
followed by a condition with 500 µl MQ-water. Then 200 µl of the diluted plasma samples 
(100pg/ml OT) were added to both plates at positions 1,2,4,5 A:H and 3,6 A:D, see table 5. In 
positions 3,6 E:H 200 µl of the zero plasma sample. 
This was followed by a first wash with 500 µl 0.5% ammonia solution/acetic acid pH 6.3 in 
each well for both plates. The flow-through after each step was collected using a deep-well 
plate. With the HLB plate the second wash consisted of 10-100% methanol and 10-100% 
acetonitrile as can be seen in table 5. This last flow-through was collected in a separate clean 
deep-well plate and the solutions were evaporated to dryness using TurboVap®96 (Zymark) 
under a stream of N2 gas at 50°C.  
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For the WCX plate the second wash also consisted of 10-100% MeOH as in table 5 but instead 
of adding the acetonitrile, columns 4-6 were washed with 10% MeOH. The flow-through from 
columns 1-3 was saved. After this columns 4-6 were washed with 10-100% acetonitrile with 
1% TFA and the flow-through was saved. The saved flow-through fractions were evaporated 
to dryness.  
To reconstitute the samples, 100 µl 5mM ammonium formate pH 4.6:acetonitrile (90/10, v/v) 
was used. For the recovery samples (REC), a concentration of 100 pg/ml OT in the final 
samples was added as well.   
Table 5. Overview over the samples used for SPE optimization. 
 1 2 3 4 5 6 
A 10% 50% 90% 10% 50% 90% 
B 10% 50% 90% 10% 50% 90% 
C 20% 60% 100% 20% 60% 100% 
D 20% 60% 100% 20% 60% 100% 
E 30% 70% 50% Blank 30% 70% 50% Blank 
F 30% 70% 50% Blank 30% 70% 50% Blank 
G 40% 80% 50% REC 40% 80% 50% REC 
H 40% 80% 50% REC 40% 80% 50% REC 
 % Methanol in wash 2 % Acetonitrile in wash 2 
 
3.6.2. Final SPE procedure 
The final SPE procedure was done using the Oasis HLB (10 µg)  96-well plate. Plasma and 
spiked plasma samples with the desired OT and IS concentrations  were thawed and  diluted 
1:1 with 4% H3PO4 in separate tubes. The plate was then conditioned as in the SPE 
optimization before the plasma samples were added. The first wash was also done according 
to the SPE optimization, followed by a second wash with 30% methanol for all samples. To 
elute the OT and IS, 500 µl 30% acetonitrile was used and the flow-through was saved and 
evaporated to dryness and reconstituted in 100 µl 2.5% formic acid, 10% acetonitrile, pH 2.5. 
The wells containing the zero plasma samples were reconstituted with the same buffer 
including OT with the same concentration as in the spiked plasma samples and used as 
controls during analysis. 
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3.7. Immunocapture assay development and optimization 
After sample preparation using either Dynabeads® or MSIATM the samples were centrifuged 
for 2 min at 1500 rpm and stored at 4°C before analysis with either the API 5000 or the T-QS 
system. 
3.7.1. Antibodies  
In table 6 the tested antibodies and their respective suppliers can be seen. Further, the 
clonality, specificity, source, isotype and presentation for each antibody is shown. The 
antibodies were stored at -20°C and thawed the same day as the sample preparation was 
performed. 
Tabel 6. Antibodies and their suppliers, clonality, specificity, source and isotype. 
Antibody (supplier) Clonality Specificity Source Isotype Presentation 
MAB5296 (Millipore) Monoclonal Anti-OT 
(clone 4G11) 
Mouse IgG Ascites fluid, 0.1%  sodium azide 
Ab67457 (Abcam) Polyclonal Anti-OT Rabbit IgG Immunogen affinity purified. 0.02% 
sodium azide, 1% BSA, PBS pH 7.4 
Ab124771 (Abcam) Monoclonal Anti-OT Rabbit IgG1 Tissue culture supernatant. 0.01% 
sodium azide, 50% glycerol, 0.05% 
BSA 
RB-13-0010B-50 
(RayBiotech) 
Polyclonal Anti-OT 
(+Biotin) 
Rabbit IgG Affinity purified. 
RB-13-0010 (RayBiotech) Polyclonal Anti-OT Rabbit IgG Affinity purified. 
SA1-9507 (Thermo Scientific) Polyclonal Anti-Mouse 
(+Biotin) 
Bovine IgG Affinity purified. 0.02% sodium azide, 
PBS 
 
3.7.2 Buffers  
The buffers used during immunocapture assay development and optimization can be seen in 
table 7. 
Tabel 7. Buffer names and their contents. 
Buffer Name Content 
Washing Buffer 1 PBS 0.05% Tween, pH 7.4 
Washing Buffer 2 PBS 0.1% BSA and 2mM EDTA, pH 7.4 
Buffer 1 PBS 0.01% BSA, pH 7.4 
Buffer 2 PBS 0.05% Tween , 1 % BSA, pH 7.4 
Elution Buffer 1 2.5% formic acid, 10% acetonitrile, pH 2.5 
Elution Buffer 2a 0.01 M phosphate buffer, 0.0027 M potassium chloride, 0.137 M sodium 
chloride, 0.2 M acetic acid, 0.2 M glycine, pH 2.5 
Elution Buffer 2b 0.01 M phosphate buffer, 0.0027 M potassium chloride, 0.137 M sodium 
chloride, 0.2 M acetic acid, 0.2 M glycine, 10% acetonitrile, pH 2.5 
Elution Buffer 3 0.1mM Citric acid pH 3.0 
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3.7.3. Dynabeads® 
For a visual flowchart of the Dynabead® principle, see figure 2. 
The development of a sample preparation procedure using Dynabeads® was  initially based 
on Life Technologies existing protocol for each Dynabeads® type. The Life Technologies 
protocols can be seen in Appendix I. The tubes used during sample preparation were 1.5, 2 
and 5 ml Eppendorf tubes and for plates Thermo Scientifics 96-Well Non-Skirted PCR plate 
(0.3ml) was used. The magnets used were DynaMagTM -2 Magnet for the tubes and 
DynaMagTM-96 Side Skirted magnet for the 96-well plates. The Dynabeads® were always 
placed at least 2 min on the magnet to ensure that all beads were collected on the tube or well 
walls. Great caution was taken to ensure that no beads were lost during pipetting. During 
antibody-bead incubation the antibody was always added in excess to ensure optimal binding 
to the  beads. An example of how the amount of beads in relation to the amount of antibody 
was calculated can be found in Appendix II. The amount of beads and antibody used for a 
specific experiment is shown in Results. The Dynabeads® and the immuno-extracted samples 
were stored at +4°C until usage. When analysing the samples, controls for each concentration 
were used. 
For the analysis of the samples during assay development the API 5000 system was used. The 
final method was then optimized and evaluated using the Xevo TQ-S system.  
3.7.3.1. Dynabeads® M-280 Streptavidin & MyOneTM Streptavidin T1 
The Dynabeads®  were resuspended in its original vial by vortexing for 60 sec. The desired 
volume was transferred to a 1.5 ml tube and 1 ml Washing Buffer 1 was added and vortexed 
together with the Dynabeads® for 10 sec. The tube was then placed on a magnet and the  
supernatant was discarded while keeping the tube on the magnet. The beads were then 
resuspended in same volume of Buffer as the initial volume of Dynabeads® taken from the 
vial. The washing step was repeated 2 times for MyOne for a total of 3 washes.  
The beads were placed on the magnet and the supernatant was discarded. The beads were 
then incubated with RB-13-0010B-50 at room temperature for 1-3 hours using the 
HulaMixer® or manual mixing by inversion every 10 min. After incubation the tube was 
placed on the magnet and the supernatant was removed. The antibody-coated beads were 
then washed 4-5 times using 1 ml Washing Buffer 1 for each washing step. The beads were 
then resuspended in 1 ml Buffer and stored. 
The desired amount of antibody-coupled beads were transferred to 13 tubes: triplicates of 
LOW, MID and HIGH and duplicates of buffer and plasma blank. 200 µl of sample was added in 
each tube and incubated together with the beads for 1-3 hours in room temperature with 
either manual mixing every 10-20 min or by using the HulaMixer®. After incubation the beads 
were washed 3 times with 200 µl Washing Buffer 1 and the supernatant from wash 1 and 3 
was saved to analyse a potential loss of OT during washing. After the last washing step the 
supernatant was removed and 200 µl Elution Buffer 2 or 3 was added and incubated together 
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with the beads for 5-10 min. The supernatant was then transferred to an analysis plate and 
stored until analysis (maximum one day after sample prep.).  
3.7.3.2. Dynabeads® Protein G 
The Dynabeads® were resuspended in its original vial by vortexing for 60 sec. The desired 
amount of beads were transferred to a tube, placed on the magnet and the supernatant was 
removed. The antibody of choice (diluted in Washing Buffer 1) was added to the beads and 
incubated with rotation using the HulaMixer® for 30-60 min. After incubation the antibody-
coated beads were placed on the magnet and the supernatant was removed and the beads 
were washed once with 1 ml Washing Buffer 1. After the washing step the supernatant was 
removed and the antibody-beads were resuspended in 1 ml Washing Buffer 1 and stored. The 
antibodies tested with the Dynabeads® Protein G were: AB911, MAB5296, Ab67457, 
Ab124771 and RB-13-0010 (see table 6). 
As described earlier the desired amount of antibody-coated beads were transferred to either 
1.5 ml tubes or a 96-well plate depending on the amount of samples to be analysed and the 
supernatant was removed. 100-500 µl plasma sample was added in at least one LOW and one 
HIGH concentration of OT. All concentrations were analysed in at least duplicate samples. The 
OT was allowed to incubate with the antibody-coated beads for 1-24 hours in room 
temperature using the HulaMixer® (tubes) or by mixing using a pipette (plates) every 10-20 
min depending on the incubation time. The 24 hour incubation was only tested with tubes and 
the HulaMixer®. After incubation the OT-antibody-bead-complex was washed 3 times 
according to previous described washes using Washing Buffer 1. When working with the 96-
well plate 100 µl washing buffer was used. After washing, 100-200 µl Elution Buffer 1, 2 or 3 
was added and incubated together with the OT-Ab-bead-complex for 5-10 min in room 
temperature. After incubation the beads were placed on a magnet, the supernatant was 
removed and transferred to an analysis plate. The analysis plate was centrifuged for 2 min at 
1500 rpm to spin  the entire sample down into the wells, leaving no residues on the well walls.  
A silicone lid was used when centrifuging. 
3.7.3.3. Dynabeads®  M-280 Sheep anti-Mouse IgG 
To prepare the beads they were handled and washed as described for the Streptavidin-beads 
but instead of using Washing Buffer 1, Washing Buffer 2 was used. Antibody MAB5296 was 
used to test the potential of the Dynabeads®  M-280 Sheep anti-Mouse IgG by comparison with 
the Protein G-beads. The desired amount of beads were incubated with the antibody for 24 
hours at +4°C using the HulaMixer®. After incubation the antibody-bead complex was washed 
three times using 1 ml of Washing Buffer 2. After the last washing step the complex was 
resuspended in 1 ml of the same buffer.  
The antibody-bead complex was incubation for 2-4 hours together with 100 µl plasma sample 
and washed three times after incubation as described for the Protein G-beads, however 
Washing Buffer 2 was used instead. To elute the OT, 100 µl of Elution Buffer 3 was used and 
incubated together with the OT-Ab-bead complex for 10 min. After incubation the beads were 
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placed on a magnet, the supernatant was removed and transferred to an analysis plate. The 
analysis plate was centrifuged for 2 min at 1500 rpm to spin  the entire sample down into the 
wells, leaving no residues on the well walls.  A silicone lid was used when centrifuging.  
3.7.4. MSIATM 
The MSIATM was performed using the Finnpipette Novus i Multichannel Electronic Pipettes (8 
well sample processing) and the MSIATM-tips mentioned in section 2.4.2.1. & 2.4.2.2. Before 
starting with the MSIATM a few preparative actions were taken. The plasma samples were 
centrifuged for 3 min at 2600 rpm to remove unwanted particles. All reagents used, including 
the MSIATM-tips, were brought to room temperature. The pipetting heights were controlled so 
that no air passed through the microcolumn during pipetting. To ensure that the tips were 
inserted properly onto the pipette , manual checking was performed. Throughout the MSIATM 
procedures pipette speed 1 was used. In the washing steps Washing Buffer 1 was used.  For 
the elution Elution Buffers 1 and 2b were tested. 
Firstly, the MSIATM-tips were prewashed using 10 iterations, a microplate volme of 250 µl and 
a pipetting volume of 150 µl. This was followed by binding of the antibody using 700-999 
iterations, a microplate volume of 120 µl and a pipetting volume of 100 µl. The antibodies 
were diluted in Washing Buffer 1 and 1.2-12 µg antibody per Protein G(or A) tip was tested. 
The Abs tested were MAB5296 and Ab124771. Due to the lack of ready-made biotinylated 
antibodies that showed good performance, or antibodies that were pure enough to enable 
biotinylation a different approach was taken with the Steptavidin-tips. SA1-9507 was pre-
incubated with MAB5296  in Buffer 2 for 2 hours in room temperatur using the Sample Hula 
Mixer. Excess of the anti-mouse antibody was used to ensure that enough MAB5296 was 
bound to capture the total amount of OT. One Ab124771 antibody had the capacity to bind 
two MAB5296 antibodies. 
Following the antibody capture a wash step, identical to the prewash was performed to 
prepare for the OT binding, where the plasma samples was diluted 1:1 with PBS and 400 µl 
was added in each well. The pipetting volume was 250 µl and 999 iterations was used.  This 
was followed by two additional washing steps and completed with an elution using 100 µl 
elution buffer, a pipetting volume of 75 µl and 100-200 iterations.  
3.7.5. Final immunocapture procedure 
The final immunocapture procedure was performed using Dynabeads® Protein G and 
antibody MAB5296. The principle of the procedure was as described in section 3.6.3.2. 
Dynabeads® Protein G with the following specifics: 500 µl beads were used and incubated 
together with 100 µl antibody stock solution (1-3 mg/ml)  pre-diluted in 2900 µl Washing 
Buffer 1. The antibody-bead incubation time was 30 min using a 5 ml tube and the 
HulaMixer®. After incubation the antibody-bead-complex was resuspended in 5 ml Washing 
Buffer 1. For the sample processing a 96-well plate was used and 60 µl of the antibody-bead 
suspension was added in each well and the supernatant was removed before 200 µl of the 
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plasma samples were added.  The OT-antibody-bead incubation time was 1 hour using manual 
mixing by pipetting every 10 min. The elution was done using 100 µl Elution Buffer 1 with an 
incubation time of 10 min. The analysis was performed using the Xevo TQ-S system.  
3.8. Qualification of the Final Method 
To evaluate the potential of immunocapture as sample preparation prior to LC-MS/MS  
analysis, precision and accuracy were tested at 10 (lower limit of quantitation; LLOQ), 
30(LOW), 45(MID) and 85(HIGH) pg/ml using six replicates. Concentration of the low QC was 
within three times the LLOQ concentration and the high QC was within 80% of the upper limit 
of quantitation (ULOQ). Accuracy was evaluated by calculating the percent deviation from the 
nominal concentration, and is reported as relative error (RE). The mean value should be 
within 15% of the nominal value, except at LLOQ, where it should be within 20% of the 
nominal value. Precision was determined by calculating the coefficient of variation (CV). The 
precision at each concentration level should not exceed 15% CV, except for the LLOQ, where it 
should not exceed 20% CV. 
In addition, the linearity of the response was evaluated at seven concentrations (n=2): 10, 25, 
40, 55, 70, 85 and 100 ng/ml using duplicates. Calibration curve performance was assessed by 
evaluating deviation of standards from the nominal concentration and evaluating the slope, 
intercept, and coefficient of determination (r2) of the weighted 1/x2 linear regression lines. 
where ± 20% from the nominal value was acceptable at the LLOQ and ±15% from the nominal 
value accepted at all other concentrations. If a calibrator did not meet these criteria, it was 
dropped from the calibration curve and the curve was recalculated. The method evaluation 
was performed using the TQ-S system.  
To compare the final immunocapture method with the final SPE method two OT 
concentrations were compared at 5 and 10 pg/ml using six replicates. The comparison was 
done using the TQ-S system. 
  
Nevin Belul 
June 2015 
30 
 
0
10
20
30
40
50
60
70
0 10 20 30 40 50 60 70 80 90 100
Ratio 
(OT/IS) 
Methanol (%) 
WCX 
0
10
20
30
40
50
60
70
0 10 20 30 40 50 60 70 80 90 100
Ratio 
(OT/IS) 
Methanol (%) 
HLB 
0
10
20
30
40
50
60
70
80
0 10 20 30 40 50 60 70 80 90 100
Ratio 
(OT/IS) 
Acetonitrile +1% TFA (%) 
WCX 
0
10
20
30
40
50
60
70
80
0 10 20 30 40 50 60 70 80 90 100
Ratio 
(OT/IS) 
Acetonitrile (%) 
HLB 
4. Results 
4.1. SPE Optimization 
To determine the optimal conditions i.e. the percentage of methanol and acetonitrile to be 
used in the SPE, an optimization of both Oasis HLB and Oasis WCX was performed.  Figure 7 
and 8 shows the OT/IS ratio versus the methanol used in percentage for both HLB and WCX. 
As can be seen in both figures, elution of OT occurs after washing with 40% methanol and 
more.  
 
   
 
 
 
 
 
Figure 9 and 10 shows the OT/IS ratio versus the acetonitrile used in percentage for both HLB 
and WCX. Further, it can be seen that after 20-30% acetonitrile is used the elution of OT 
remains relative constant for both methods. 
 
 
 
  
 
 
 
Figure 7. Ratio of OT/IS versus methanol (%) for Oasis HLB. Figure 8. Ratio of OT/IS versus methanol (%) for Oasis WCX. 
Figure 9. Ratio of OT/IS versus acetonitrile (%) for Oasis HLB. Figure 10. Ratio of OT/IS versus acetonitrile (%) for Oasis WCX. 
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4.2. Immunocapture Assay Development 
During the immunocapture assay development several experiment were conducted. In this 
section a selection of these experiments are presented. This selection is based on the 
importance of each experiment in regard to developing and choosing the final method.  
4.2.1. Dynabeads® M-280 Streptavidin & MyOneTM Streptavidin T1 
The experiments carried out using the Streptavidin-beads and the biotin labelled anti-OT Ab 
RB-13-0010B-50 demonstrated inconclusive results. A selection of these results, shown in 
chromatograms generated by API 5000, can be seen in Appendix III.  
4.2.2.Choice of Antibody  
During the assay development using the Protein G-beads, four different antibodies were 
tested to determine the antibody with greatest potential for further development and 
optimization. In table 8, the recoveries for each antibody is shown. The recovery is the 
amount of pure product recovered versus the amount of crude material used.  The recovery is 
a mean value calculated from duplicate samples (1 ng/ml OT). During the Ab-bead-complex 
incubation (1 hour) 1.2 mg beads were incubated with 13.75 µg Ab124771, 20 µg Ab67457 
and 20 µg RB-13-0010B-50 respectively. Since MAB5296 had an unknown concentration of 1-
3 mg/ml stock solution, due to the fact that it was presented in ascites fluid, three different 
concentration ranges were tested: 10-30, 12.5-37.5 and 20-60 µg. The recovery for MAB5296  
in table 8 is a mean value calculated from the average value of duplicate samples for each 
concentration range.  
During the incubation with OT, 100 µl plasma + 100 µl PBS was used to enable sufficient 
mixing since 1.5 ml tubes were used. The incubation time was 30 min and Elution Buffer 2a 
was used. The analysis was performed using the API 5000 system and the recovery was 
calculated using the chromatograms generated. The immune-prepared sample was compared 
to a control sample (1 ng/ml OT). As can be seen in table 8, the Millipore antibody MAB5296 
showed the greatest recovery (11%). 
Table 8. Antibody, the amount of antibody-bead-complex per well in µg and their respective recovery. 
Antibody  Ab-bead-complex per well (ug) Recovery 
MAB5296 (Millipore) 36 11% 
Ab67457 (abcam) 36 3.5% 
Ab124771 (abcam) 36 2.6% 
RB-13-0010B-50 (RayBiotech) 36 7.0% 
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4.2.3. Comparison of Coupling Mechanisms  
4.2.3.1. Dynabeads® Protein G and Sheep Anti-Mouse 
Since the Streptavidin-beads showed no potential the protein G-beads were compared to the 
Sheep Anti-Mouse beads, using the antibody exhibiting the greatest potential (MAB5296). 
During the preparation of antibody-bead-complex 50 µl of bead stock solution was incubated 
with 10-30 µg Ab each for 30 min. For the incubation with the plasma samples a 96-well plate 
was used and 100 µl plasma (1 ng/ml OT) was added in each well. The samples were 
incubated for four hours in duplicates. For the Protein G-beads 100 µl Elution Buffer 2a was 
used and for the Sheep Anti-Mouse-beads  100 µl of Elution Buffer 3 was used. Two different 
amounts of Ab-bead-complex were tested and analysed using API 5000. Table 9 shows the 
recovery (%) for each bead type and Ab-bead-complex amount. As can be seen, the 
Dynabeads® Protein G beads show a greater recovery compared to the Sheep Anti-Mouse-
beads with a recovery ranging from 38 to 40% compared to 21 to 22%.  
Table 9. Antibody, the amount of antibody-bead-complex per well in µg and their respective recovery. 
Dynabeads® type Antibody-bead-complex per well (µg) Recovery 
Sheep Anti-Mouse 25 22 % 
Sheep Anti-Mouse 35 21 % 
Protein G 25 40 % 
Protein G 35 38 % 
4.2.3.2. MSIA Protein G, AG & Streptavidin 
To compare the Protein G-beads with MSIA a couple of experiments using MSIA were 
conducted. Unfortunately, the experiments carried out using the MSIA-tips generated 
inconclusive results. The Protein A and AG tips were tested with 2 different antibodies, one of 
them being the MAB5296 antibody. The streptavidin-tips were tested using a pre-incubated 
solution of the biotinylated SA1-9507 and the MAB5296. Different concentrations of the 
antibodies and a few different elution buffers were tested. A selection of these results, shown 
in chromatograms generated by the API 5000 system, can be seen in Appendix III.  
4.3. Immunocapture Optimization 
Since the Dynabeads® Protein G together with MAB5296 was the method showing greatest 
potential during assay development, this was the immunocapture method optimized. During 
optimization the focus was on increasing the yield and the signal. All optimization 
experiments were analysed using Xevo TQ-S system. In this section a selection of these 
experiments are presented. This selection is based on the importance of each experiment in 
regard to developing and choosing the final method.  
4.3.1. Elution  
The first step in the optimization was to determine which elution buffer to move forward 
with. Therefore three experiments were conducted using Elution Buffer 1, 2b and 3. The 
plasma samples were analyzed in duplicates using 30 µl antibody-bead-complex in each well. 
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During the preparation of antibody-bead-complex 1.5mg beads/ml and 10-30µg antibody/ml 
was used. The plasma samples contained 100 pg IS/ml plasma as well. The standard samples 
were OT spiked solutions of each elution buffer, including 100 pg IS/ml.  
It was quickly noticed that Elution Buffer 2a was not suited for the TQ-S system due to the 
high salt content and therefore no reliable results were obtained. The results for the other 
elution buffers can be seen in table 10. Here it should be noted that unacceptable variations 
occurred at three concentrations for Elution Buffer 1 and at four concentrations for Elution 
Buffer 3 (red values). For the concentrations were the variation in QC area was acceptable, the 
ratio of the QC area/Standard area was calculated. For Elution Buffer 1 the ratio ranged from 
19-28% and for Elution Buffer 3 it ranged from 21-25%. No larger difference was found 
between the two elution buffers and since Elution Buffer 1 has shown to be successful 
(Osgood, et al.), it was chosen for the sample preparation.  
In order to be able to calculate the yield correctly the IS (100 pg/ml) was chosen to be added 
together with the elution instead.  
Table 10. The QC – and Standard areas for seven OT concentrations for Elution Buffer 2a and 3 and the QC Area/Standard 
Area ratio (%) for the areas with acceptable variation. 
 Elution Buffer 1    
OT conc. 
(pg/ml) 
QC-area 1 QC-area 2 Standard-area QC-area/Standard-area (%) 
10 28 11 180  
25 60 80 380 21 
40 170 95 640  
55 190 180 860 25 
70 220 210 1030 24 
85 280 320 1170 25 
100 270 520 1380  
     
  Elution Buffer 3    
OT conc. 
(pg/ml) 
QC-area 1 QC-area 2 Standard-area QC-area/Standard-area (%) 
10 47 18 190  
25 84 30 340  
40 160 80 480  
55 200 120 740  
70 220 180 890 19 
85 300 260 1230 24 
100 390 370 1390 28 
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When using IS (100 pg/ml) with the elution (100 µl) instead a much smaller variation was 
obtained (see Appendix IV) and the yield could be calculated correctly. The QC area/Standard 
area varied from 29-37%, an improvement from previous experiment using IS during the 
sample preparation instead. Still, a low percentage of OT seemed to be extracted during the 
sample preparation and therefore two more experiments were conducted: 150 µl elution 
buffer was used instead of the normal volume of 100 µl and 50 µl 0.03% BSA was added in 
each well of the analysis plate prior to addition of the sample to be analyzed. These 
experiment were conducted to (1) investigate if a greater volume of elution buffer improved 
the recovery and (2) to analyze if BSA reduced a potential unspecific binding. When using 150 
µl elution the ratio varied from 26-41% and when adding 50 µl 0.03% BSA the ratio varied 
from 25-35%. These experiments did not improve the amount of OT being extracted and 
therefore continuation with 100 µl of Elution Buffer 1 proceeded.  The results can be seen in 
table 11.  
Table 11. OT QC Area/OT standard Area (%) for 100µl, 150µl and 100µl + 50µl 0.03% BSA Elution Buffer 2a. 
OT conc. 
(pg/ml) 
OT QC Area/OT standard 
Area (%) 
100ul Elution Buffer 1 
OT QC Area/OT 
standard Area (%) 
150ul Elution Buffer 1 
OT QC Area/OT standard Area 
(%) 
100ul Elution Buffer 1  
+ 50uL 0,03% BSA 
10 37 26 34 
25 36 29 35 
40 34 41 28 
55 32 32 32 
70 31 36 31 
85 30 36 28 
100 29 33 25 
 
4.3.2. Antibody-bead-complex Amount 
To investigate how the amount of antibody-bead-complex per well influenced the signal, three 
different amounts were evaluated. During the preparation of antibody-bead-complex 50 µl of 
bead stock solution was incubated with 10-30 µg antibody for 30 min. For the incubation with 
the plasma samples a 96-well plate was used and 100 µl spiked plasma, in seven different 
concentrations, was added in each well. The samples were incubated for 1 hour in duplicates. 
Elution was done using 100 µl Elution Buffer 1 including 100 pg/ml IS.  
Figure 11 shows the signal to noise ratio (S/N) for each concentration and antibody-bead-
complex amount: 60 µg, 90 µg and 120 µg. As can be seen, there is no larger difference in S/N. 
However, 90 µg display the highest signal for all OT concentrations except 55 pg/ml where 60 
µg gives the highest signal. Based on this, 90 µg antibody-bead-complex was used for the 
remaining optimization experiments. 
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Figure 11. S/N for seven OT concentrations (10, 25, 40, 55, 70, 85 and 100 pg/ml) for three different antibody-bead-complex 
amounts (60, 90 and 120 µg) 
 
4.3.3. Incubation Time 
The recovery when using 1 hour incubation in room temperature can be seen in table 12. 
When incubating the samples a 96-well plate was used and manual mixing by pipetting every 
10-15 min was performed. Table 11 shows that there is a small decrease in recovery with 
increasing OT concentration. The recovery is calculated as an average from duplicate samples 
compared to a control sample for each concentration. The recovery ranges from 25.6-47.5%.  
Table 12. The recovery (%) after sample preparation (1 hour incubation) for different OT concentrations. 
OT Concentration (pg/ml) Recovery (%) 
10 47.5 
25 37.5 
40 31.8 
55 31.9 
70 31.1 
85 30.6 
100 25.6 
 
Two more experiments were conducted where manual mixing by pipetting was done with less 
frequency (two vs. three times during the 1 hour incubation). Unfortunately, this did not show 
an increase in recovery. To investigate the influence of incubation time and mixing on 
recovery an experiment using continuous rotation with the HulaMixer® for 24 hours was 
done. To decide the potential of this experiment, two concentrations were analysed: 10 and 
100 pg/ml. The results showed that the recovery was 28.2 and 19.1% for 10 and 100 pg/ml 
respectively (table 13).  
0
50
100
150
200
250
300
0 20 40 60 80 100 120
S/N 
 OT concentration (pg/ml) 
60 µl
90 µl
120 µl
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Tabel 13.  The recovery (%) after sample preparation (24 hour incubation) for different OT concentrations. 
OT Concentration (pg/ml) Recovery (%) 
10 28.2 
100 19.1 
 
4.3.4.  Sample Volume 
As a last step in the optimization, 200 µl plasma sample was used instead of 100 µl while still 
remaining an elution buffer volume of 100 µl i.e. concentrating the sample to be analysed with 
a factor 2. This was performed in order to reach a detection signal that would enable 
quantification with a LLOQ of 10 pg/ml. Duplicate samples were tested in seven 
concentrations and the response of the analyte (OT) was compared to the response obtained 
when using 100 µl sample volume. The response was calculated as a mean value using 
duplicate samples for each OT concentration. The results showed more than a two-fold 
increase for all concentrations when using 200 µl sample volume, except for 10 pg/ml where 
the increase was 42%, still a clear improvement compared to previous experiments (table 
14). The increase in response was the ratio calculated as Response 200 µl/Response 100 µl. 
Based on this improvement in OT response this was chosen to be the final method to qualify 
i.e. using 200 µl sample volume while keeping an elution volume of 100 µl. 
Table 14. The OT response when using 100 µl and 200 µl sample volume respectively and the increase in response calculated 
as the ratio (Response 200 µl/Response 100 µl). 
OT nominal  conc. (pg/ml) Response 
(100 µl) 
Response 
 (200 µl) 
Increase in response 
(Response 200 µl/Response 
100 µl ratio) 
10 0.06 0.08 1.42 
25 0.11 0.29 2.73 
40 0.16 0.37 2.30 
55 0.21 0.47 2.21 
70 0.28 0.65 2.29 
85 0.28 0.63 2.21 
100 0.31 0.83 2.67 
 
4.3.5. Bead Capacity 
As a final step the antibody-bead-complex capacity was tested since an increase in plasma 
volume indicated an unexploited bead capacity. The experiment was done by increasing the 
plasma sample volume and investigating the OT response. Sample preparation using 300, 400 
and 500 µl plasma was tested. The result for the samples containing 10 pg OT/ml (mean value 
of duplicates)  can be seen in figure 12 and the figure shows an increase in response with 
increasing plasma volume. 
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Figure 12. OT response for sample preparations using 300, 400 and 500 µl plasma containing 10 pg OT/ml plasma. 
4.4. Qualification of the Final Method 
The qualification of the final method was performed as described in section 3.7. Qualification 
of Final Method using the experimental method described in section 3.6.3. Final 
immunocapture procedure. 
A 1/x2 weighting was used to fit a linear least squares regression calibration curve to the 
response versus concentration data. Two versus three calibration points were deleted in run 
1 and 2 respectively. After removal of these points good linearity in the range of 10 pg/mL to 
100 pg/mL was achieved, with r2  values of 0.9857 and 0.9866 for the two qualification runs. 
These two qualification runs yielded lines with slopes of 0.006399 and 0.006927 and  y-
intercepts of 0.02808 and 0.02608 respectively. Table 15 shows the calibration points for the 
two runs, where the deleted calibration points are shown in red color. The CV and RE are 
calculated without these deleted points and ranges from 1 to 14% and -4 to 6% respectively. 
Table 15. Standard curve results. SD, standard deviation; CV, coefficient of variation; RE, relative error. Calibrations points 
deleted are shown in red. 
    CAL 1 CAL 2 CAL 3 CAL 4 CAL 5 CAL 6 CAL 7 
Nominal conc.   10 25 40 55 70 85 100 
(pg OT/mL plasma)         
Observed conc. RUN 1 4,10 21,9 33,6 42,0 75,2 82,6 96 
(pg OT/mL plasma) 10,3 26,5 43,3 51,9 76,1 92,8 98,6 
     RUN 2 8,7 23,5 30,0 57,8 68,6 72,8 98,7 
    11,3 18,3 24,3 59,0 77,6 85,9 98,9 
Average:   8,6 22,6 32,8 52,7 74,4 83,5 98,1 
SD:   3,2 3,4 8,0 7,8 4,0 8,3 1,4 
CV (%):   13 10 14 7 5 10 1 
RE (%):   1 -4 -4 2 6 -2 -2 
0
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n   4 4 4 4 4 4 4 
For the QC samples the precision (reported as CV%) did not exceed 15% , while the accuracy 
(expressed as relative error, RE) did not vary more than  -8% from the expected value, except 
for the highest QC were the accuracy varied +33% and +23% from the expected value.  
Analysis of the four QC samples yielded a precision between 12% and 15% and an accuracy 
ranging from 92 to 102% (excluding HIGH QC) (table 16). 
Table 16. Precision and Accuracy. LLOQ, lower limit of quantification; QC, quality control; SD, standard deviation; CV, 
coefficient of variation (measure of precision); RE, relative error (measure of accuracy). 
 LLOQ LOW QC MID QC HIGH QC 
Nominal conc. (pg OT/mL plasma) 10,0 30,0 45,0 80,0 
RUN 1     
Observed conc. (pg OT/mL plasma) 9,40 25,7 41,7 95,6 
 10,6 23,7 39,8 84,7 
 6,90 27,1 37,3 120 
 9,20 29,3 39,8 96,1 
  9,90 34,6 43,2 96,9 
  9,30 33,2 53,2 97,4 
Mean: 9,20 28,9 42,5 98,4 
SD: 1,25 4,28 5,61 11,5 
CV (%): 14 15 13 12 
RE (%): -8 -4 -6 23 
n 6 6 6 6 
RUN 2     
Observed conc. (pg OT/mL plasma) 9,90 27,5 44,8 103 
 11,1 25,4 42,7 91,4 
 7,20 29 40,1 129 
 9,60 31,5 42,8 104 
  10,5 37,2 46,5 105 
  9,70 35,6 57,3 105 
Mean: 9,70 31,0 45,7 106 
SD: 1,33 4,64 6,08 12,4 
CV (%): 14 15 13 12 
RE (%): -3 3 2 33 
n 6 6 6 6 
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4.5. Comparison of Final Immunocapture Method and SPE Method 
When comparing the immunocapture and SPE method, samples with plasma blank and OT 
concentration of 5 and 10 pg/ml were tested. OT had a tr  of approximately 4.6. Figure 13 
shows the results for the plasma blanks. In the upper chromatogram corresponding to the SPE 
method no detectable OT peak can be seen. However, in the lower chromatogram 
corresponding to the immunocapture method an OT peak is detected with a S/N of 2.89. 
Figure 14 shows the result for the samples with 5 pg OT/ml plasma.  For the SPE (upper 
chromatogram) the results show a S/N of 4.01 and for the immunocapture (lower 
chromatogram) the S/N is detected to be 25.45. For the samples containing 10 pg OT/ml the 
S/N  is 0.97 for the SPE and 41.44 for the immunocapture method (figure 15).  
 
 
 
Figure 13. Chromatogram for the plasma blanks of  the SPE(upper) - and immunocapture(lower) method respectively. 
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Figure 14. Chromatogram for plasma samples containing 5pg OT/ml  of  the SPE(upper) - and immunocapture(lower) 
method respectively. 
 
 
 
Figure 15. Chromatogram for plasma samples containing 10pg OT/ml  of  the SPE(upper) - and immunocapture (lower) 
method respectively 
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TIC (Oxytocin)
3.25e3
S/N:PtP=41.44
3.03
4.30
3.863.43
5.83
5.43
5.224.96
5.28
5.755.64
6.005.95
OT
OT
IE 10 pg/ml OT in plasma
SPE 10 pg/ml OT in plasma
Time
3.00 3.20 3.40 3.60 3.80 4.00 4.20 4.40 4.60 4.80 5.00 5.20 5.40 5.60 5.80 6.00
%
0
100
3.00 3.20 3.40 3.60 3.80 4.00 4.20 4.40 4.60 4.80 5.00 5.20 5.40 5.60 5.80 6.00
%
0
100
IM_29Apr2015_b5 Sm (Mn, 1x2) 1: MRM of 2 Channels ES+ 
TIC (Oxytocin)
1.94e3
S/N:PtP=4.01
4.27
3.03
3.84
3.54
3.25
3.39
3.72
3.60
3.88
3.89
3.98
4.02
4.17
4.30
4.32
4.37
4.524.46
4.89
4.85
4.82
4.78
4.91
4.92
5.885.03
4.96 5.10 5.84
5.14
5.23 5.26
5.47
5.32 5.54
5.745.62
5.96 6.01
IM_29Apr2015_b21 Sm (Mn, 1x2) 1: MRM of 2 Channels ES+ 
TIC (Oxytocin)
1.74e3
S/N:PtP=25.45
3.03
3.92
3.883.84
3.71
4.05
4.39 4.52
5.99
5.84
4.70
5.655.585.01
4.78
5.14 5.23 5.435.38 5.76
5.94
OT
OT
IE 5 pg/ml OT in plasma
SPE 5 pg/ml OT in plasma
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5. Discussion 
During the immunocapture assay development and optimization a great amount of 
experiments were conducted, some more successful than others. To investigate the potential 
of immunocapture techniques as sample preparation both SPE optimization and 
immunocapture assay development and optimization was performed. The SPE method, the 
previously established sample preparation method prior to LC-MS/MS analysis was used to 
evaluate the successfulness of the developed immunocapture assay. 
5.1. SPE Optimization 
As can be seen in figures 7-10 the results are more or less identical for both HLB and WCX. 
This confirms that OT does not bind stronger to the WCX and thus does not take advantage of 
the ion binding mechanism of WCX. The core of the WCX material is in fact HLB and this 
explains the similar results. In consultation with Research Scientist Sara Stensson the HLB 
plate was chosen as the final SPE plate, since the WCX plate did not improve the results. 
Elution occurred after washing with 40% methanol (figure 7) and therefore 30% methanol 
was chosen for the second wash. It is crucial not to elute OT during the washing steps. For the 
elution 30% acetonitrile was chosen. A higher acetonitrile percentage did not increase the 
elution of OT and is therefore not necessary (figure 9).  
5.2. Immunocapture Assay Development 
During the immunocapture assay development the potential of different coupling mechanisms 
for both the Dynabeads® and the MSIA were investigated. Further, the potential of different 
antibodies were tested. Due to the time limit of the project, choosing of the coupling 
mechanism and the antibody having the greatest potential, had to be made based on a limited 
amount of experiments. 
Unfortunately, the Dynabeads® experiments carried out utilizing the streptavidin-biotin 
interaction gave inconclusive results. There was no success in capturing OT during the sample 
preparation. To make sure that the OT was not washed off during the washing steps, the 
supernatant from wash 1 and 3 was analysed. No OT was detected in the supernatant 
obtained from the washing steps either. Also, two different elution buffers were tested giving 
no difference in the results. Since two different beads were tested with different antibody 
concentrations and elution buffers, the conclusion is that the problem lies in the capacity of 
the biotinylated anti-OT antibody. The supply of biotinylated anti-OT antibodies in the 
commercial market was found to be very poor and no replaceable antibody could be found. 
Based on the results and the lack of biotinylated anti-OT antibodies on the market no more 
experiment were conducted using these types of Dynabeads®. The strong streptavidin-biotin 
interaction would have made these beads a greater candidate than the protein G-beads since 
the interaction between protein G and antibody is not near the strength of streptavidin-biotin. 
If a proper biotinylated OT-antibody was available on the market this would probably be the 
Nevin Belul 
June 2015 
42 
 
best choice since the antibody would not have been washed off during elution and the beads 
could have been reused saving both time and money.  
Due to the fact that the biotinylated antibody was found to be unsuccessful, the choice of 
antibody was done by testing different antibodies with the Protein G-beads. The Protein G-
beads were used to be able to compare the results using the same coupling technique with 
MSIATM. The choice of antibody was based on recovery calculated in regard to the signal for 
the immunocapture-prepared sample compared to the control signal (1 ng OT/ml). As can be 
seen in table 8 the antibody showing the greatest potential is the Millipore antibody 
MAB5296, with a recovery of 11%, this can be explained by the fact that the antibody is 
monoclonal and therefore likely to be very specific towards OT. This antibody was chosen for 
further development and optimization. Due to the time limit it was assumed that MAB5296 
was the antibody best suitable for the Sheep Anti-Mouse-beads as well. This was done to 
determine whether to proceed optimization with the Protein G-beads or the Sheep Anti-
Mouse-beads.   
To determine which Dynabeads® type to continue the optimization with, the Protein G-beads 
and the Sheep Anti-Mouse-beads were compared using the chosen antibody MAB5296. Two 
different amount of antibody-bead-complex per sample was tested and the results showed 
that the Protein G-beads gave a higher recovery of 38 and 40% compared to 21 and 22% 
(table 9) i.e. the Protein G-beads showed a recovery twice as high.  Further, it can be seen that 
the recovery when using the smaller amount of antibody-bead-complex per well is 1 and 2 % 
higher for the Sheep Anti-Mouse and  Protein G-beads respectively. Since it only differs 1 and 
2% it is not possible to state that the difference in recovery is due to the antibody-bead-
complex amount used.  
To investigate the potential of MSIATM a couple of experiments were conducted using both 
Protein A, Protein AG and Streptavidin tips. Unfortunately, the results were disappointing and 
could not compete with the potential of the Protein G-beads. During the development of 
MSIATM a Field Application Specialist (MSIA Consumables & Platform) from Thermo Fisher 
was of assistance. Even though the successful antibody MAB5296 was used for the MSIA 
experiments, there was no detectable OT in the chromatograms. As the Field Application 
Specialist stressed, the capacity and purity of the antibody is of great importance during 
MSIATM development. Why MAB5296 did not work with MSIATM may be explained by the 
presentation of the antibody. Since the antibody is presented in ascites fluid, it is not affinity 
purified and may contain other IgG that are not specific to OT as well. Therefore there is a risk 
of other competing mouse IgG binding to the Protein G. It was discussed whether or not to 
affinity purify the antibody but with risk of losing the antibody e.g. if the antibody-antigen 
interaction is too strong, causing an unsuccessful elution of the antibody, this approach was 
not taken.  
Due to the lack of ready-made biotinylated antibodies that showed good performance or 
antibodies that were pure enough to enable biotinylation, a different approach was tested 
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with the streptavidin-tips where pre-incubation of MAB5296 and biotinylated anti-mouse 
antibody was performed. Still, inconclusive results were obtained. When pre-incubating, the 
binding of the two antibodies may have caused steric hindrance for the OT binding. Instead of 
pre-incubating, the antibodies can be used directly with MSIATM instead. Prior to capturing the 
anti-OT antibody the anti-mouse antibody is captured instead. Even though further 
development of MSIATM could have yielded in detecting OT,  the limitation of antibodies and 
time limit lead to the decision to focus on optimizing the Protein G beads instead. However, if 
having a successful antibody, MSIATM would have been simple to automatize and handle. 
5.3. Immunocapture Optimization 
Even though the monoclonal antibody chosen for optimization is presented in ascites fluid 
and may therefore contain other antibodies as well, the affinity of the antibody seems high. 
During the optimization parameters such as elution, antibody-bead amount, incubation time, 
sample volume and bead capacity were tested and the influence of each parameter was 
analyzed. The biggest problem during the optimization was to increase the OT recovery. The 
yield, when testing different elution experiments, was calculated as the ratio between the OT 
QC-area and OT standard-area and ranged from 19 to 28% when using IS during the sample 
preparation and 25 to 41% when using IS in the elution. To be able to correctly calculate the 
yield, it was necessary to add IS to the elution buffers instead. The elution as parameter did 
not seem to influence the yield. No clear pattern in recovery could be seen when changing the 
elution buffer or the elution buffer amount. Therefore the low recovery does not seem to be 
caused by the elution process.  
The second parameter to be tested was the antibody-bead-complex amount and to examine 
whether the capacity was too low to capture the total amount of OT, even if working with in a 
very low concentration level. Three different amounts were tested but the results showed no 
sign of an increased signal with an increased amount. The difference in signal between the 
different amounts was very small but for all concentrations except one (55 pg/ml) 60 µg 
showed a slight increase in signal. Due to the minor increase in signal it is not possible to state 
that the increase depends on the amount of antibody-bead-complex used, it can simply be a 
coincidence. Even if no explanation can be made, 90 µg showed a minor increase and was the 
amount chosen. If the problem of the low yield was the antibody-bead-complex amount the 
highest amount of 120 µg would have generated the highest signal.  
When working with a large amount of samples, a 96-well plate was used during sample 
preparation. Unfortunately no appropriate mixer could be found and sedimentation of the 
beads occurred between every manual mixing occasion. According to Life Technologies, a 
continuous mixing/rotation of the beads is very important during incubation to enable a 
sufficient capture of OT. To determine if an increase in incubation time and continuous mixing 
had an impact on the recovery a 1 hour incubation, using a 96-well pate and mixing by 
pipetting every 10 min, was compared to a 24 hour incubation using the HulaMixer 
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(continuous rotation of the tubes). Both incubations were performed in room temperature. 
The results show that an increase in incubation time did not have a positive effect on the 
recovery that ranged from 19.1 to 28.2% compare to the 1 hour incubation were the recovery 
was 25.6-47.5%. For the 24 hour incubation only two concentrations were tested at: 10 and 
100 pg OT/ml plasma, to explore the potential of this method change. The negative effect on 
recovery may be due to a too long incubation in room temperature causing a dissociation of 
the antibody and the Protein G. If this was the case the antibody, together with the OT, was 
washed off during the washing steps and an incubation at +4°C could possibly have prevented 
it. 
To ensure that the low recovery was not due to a capacity issue with the antibody, the sample 
volume was increased and the antibody-bead-complex capacity was investigated. When 
increasing the sample volume from 100 to 200 µl approximately a twofold increase in OT 
response was detected, meaning that the capacity of the antibody-bead-complex was not the 
problem. This increase in response and hence the detection signal, made it possible to use a 
LLOQ of 10 pg/ml.   
The qualification of the method was therefore done using 200 µl plasma but to further 
investigate the antibody-bead-complex capacity an additional experiment was done where 
300, 400 and 500 µl plasma was used. The increase in response when using 300 and 400 µl 
plasma was approximately 40% while the difference between using 400 and 500 µl plasma 
was approximately 25%. An increase in response indicates that the used amount of antibody-
bead-complex has a capacity to endure more plasma than the original amount used. To 
determine the capacity an experiment using larger volumes of plasma should be conducted. 
The increase in response shows that the low recovery is not due to capacity issues of the 
antibody-bead-complex. Why then, is the recovery only between 30-40% when working with 
100 µl plasma?  
The most probable explanation is the unsufficient mixing during incubation generating an 
unsatisfactory binding of the OT. Due to the time limit no more experiments to investigate this 
were conducted, however additional experiments testing different incubation times and using 
the HulaMixer® for continuous mixing can be done to optimize the incubation. Another 
explanation can be unspecific binding, which often is a problem when working with small 
peptides like OT. One experiment was conducted where BSA was added in the analysis plate 
prior to addition of the purified sample to reduce the unspecific binding but the results 
showed no improvement in recovery. Additional experiment to investigate the unspecific 
binding can be done. A third explanation can be that the antibody and antigen (OT) reach 
equilibrium when 30-40% of the OT in the sample has bound to the antibody, nevertheless to 
determine this, the mixing and unspecific binding should be investigated first. 
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5.4. Qualification of the Final Method 
The qualification of the final method was done by testing the linearity at seven concentrations 
and precision and accuracy at four QC-levels. The back calculated concentration should be 
within ±15% of the nominal concentration except for LLOQ where it should be within ±20%. 
At least 75% of the calibration samples, with a minimum of six concentration levels, must 
fulfil this criterion. After removing 4 calibration points, good linearity in the range of 10 to 
100 pg/ml was achieved. The CV was no more than 14 % including the LLOQ and the RE 
varied no more than -4 to 6%. For the QC-samples the precision and accuracy was qualified. 
The precision was measured in CV with the highest value at 15% (30 pg/ml) which fulfilled 
the criterion for precision. The accuracy was measured in RE and varied no more than -8% 
from the expected value except for the HIGH QC-sample where the accuracy was found to be 
+23% an +33% from the expected value even though the precision was according to the 
criterion. When looking at the measured concentration at QC 80pg/ml, it seems to be varying 
very close to 100 pg/ml and since linearity was achieved at these concentration (both at 85 
and 100 pg/ml) it seems highly likely that the QC samples used as 80 pg/ml was in fact 
samples spiked with 100pg/ml. This would explain the good precision but the great margin of 
error in accuracy. Excluding the QC-samples at 80pg/ml the final immunocapture method 
exhibited a good linearity and a precision and accuracy according to the criterions. A further 
improvement to improve precision would be to include the IS during the immunocapture to 
compensate for variations during this process.  
5.5. Comparison of Final Immunocapture Method and SPE Method 
To determine if the developed immunocapture method was an improvement from the 
optimized SPE method they were compared at two concentrations: 5 and 10pg/ml as well as 
endogenous levels in blank plasma. When analysing the blank plasma samples no endogenous 
levels of OT could be detected with the SPE method, however when using the developed 
immunocapture method OT was detected with a S/N of 2.89 (figure 13). For the samples 
containing 5 pg/ml the S/N was 4.01 for the SPE and 25.45 for the immunocapture method. 
By looking at the background noise in figure 14 it is very clear the sample prepared with 
immunocapture shows a very clear OT peak distinctly distinguish from the background while 
the sample prepared with SPE has disturbing peaks almost as high as for the OT. The same 
goes for the sample were 10 pg OT/ml plasma was used. Here the S/N for the SPE was 0.97 
compared to 41.44 for the immunocapture method (figure 15). A high S/N indicates a high 
signal for the analyte compared to the background signal. These impressive results for the 
immunocapture method shows that a highly pure sample containing OT was generated and 
that even low endogenous levels of OT in blank plasma could be detected. The background 
noise generated by the complex matrix plasma, was drastically reduced compared to the SPE 
and the immunocapture method seems to have a great potential for a method able to quantify 
levels down to the low pg/ml.   
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6. Conclusion 
The proposed approach to use immunocapture techniques for sample preparation prior to LC-
MS/MS analysis was shown to have great potential for detecting OT at low concentration  
levels. With the available commercial antibodies in mind, the Dynabeads® were successful 
whereas the MSIATM had higher demands on the antibody and the supply of antibodies on the 
market was unsatisfactory. The immunocapture method showing the most promising results 
were the Dynabeads® Protein G together with the monoclonal antibody MAB5296. Problems 
with low recovery was come across but to be able to quantify the method using a LLOQ of 10 
pg/ml, the sample volume was increased to 200 µl generating a two-fold increase in OT 
response. The qualification of the final method showed a good linearity and precision and 
accuracy when excluding the HIGH QC-sample that most likely was wrongly spiked. When 
comparing the developed method with the SPE method is was very clear that the 
immunocapture technique enabled a very pure extract where endogenous levels of OT was 
detected in blank plasma whereas OT levels of 10 pg/ml could not be distinguished from the 
background noise when using SPE. These observations show that immunocapture is a 
successful technique for extracting an analyte at very low concentrations in complex matrices 
such as plasma. The specificity towards the analyte enables a very pure extract to be analysed.   
For future research, a full validation of the final method should be conducted. Also, further 
optimization of the Dynabeads® would be interesting. A development of a pure presented 
monoclonal antibody with high specificity would be very satisfying, enabling a biotinylation 
and also the possibility to do a re-evaluation on the merits of the MSIATM system. With MSIATM 
an automation would be simple to implement whereas it would be more of a challenge, but 
still interesting to try to automate the Dynabeads® method for future use. Further, it would 
also be interesting to develop an on-line immunocapture method coupled to a LC-MS/MS 
system.  
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Appendix I: Life Technologies protocols for the different 
Dynabeads® types 
The different protocols from Life Technologies as referred to in section 3.6.3. Dynabeads® can 
be seen below in the order. 
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Appendix II: Example of calculation for sample preparation using 
Dynabeads®   
Dynabead
®
 concentration: 30 mg/mL        
Capacity antibody: 8 ug Ab/mg beads       
Mw: IgG: 150 000  Da        
Mw: oxytocin: 1007 Da        
          
Example          
Desired HIGH-sample: 1 ng/mL        
Sample volume: 100 uL        
Bead volume: 30 uL        
Wanted oxytocin capacity 
(mass): 0,2 ng Calculation: Desired HIGH sample x Sample volume (ml)    
Wanted oxytocin capacity 
(moles): 0,2 pmoles Calculation: 
 
(Wanted OT capacity (mass)x(10^-9))/Mw: 
OT    
Required amount of antibody 
in each well:  0,01 ug Calculation: 
 
Mw: IgG/2*wanted OT capacity 
(moles)*1000000   
    2 mole OT/mole ab     
Antibody-bead coupling                 
Used a higher amount antibody and beads than required  to ensure sufficient binding to beads and also to ensure enough 
antibody-bead-complex to capture OT.  
   
Total amount antibody 
required: 
0,3 (used 10 
instead) ug  Calculation: 
Required amount of antibody in each well/(bead 
volume/1000)   
Total amount of beads 
required: 
1,25 (10 ug 
Ab) mg Calculation: 
 
Total amount antibody required/capacity of 
antibody   
Bead volume required during 
coupling: 
42(used 50 
instead) uL Calculation: 
 
Total amount of beads required/concentration of 
beads in original vial x 1000  
          
 
Appendix III: Chromatograms 
Figure 1-3 show the results from an experiment conducted with Dynabeads® Streptavidin M-
280 using 1ng OT/ml plasma. Figure one, the control containing elution buffer spiked with 1 
ng OT/ml, shows an intensity of 4945 cps and a tr of 1.53 min for OT. Figure 2 represents the 
sample-prepared plasma sample (1ng OT/ml plasma) and the OT cannot be distinguished 
from the background noise even if the background noise only shows an intensity of 60 cps. 
Figure 3 shows the result of the supernatant collected from the first wash of the plasma 
sample in figure 2. No OT can be seen here either i.e. the OT has not been eluted during the 
washing steps.   
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Figure 2. Streptavidin M-280  control (1 ng OT/ml). OT tr 1.53 min. 
 
Figure 3. Streptavidin M-280 plasma sample (1ng/ml). 
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Figure 4. Streptavidin M-280 plasma sample (1ng/ml) wash 1. 
Figure 4-6 show the results from a MSIA experiment conducted using Protein G and AG tips 
together with MAB5296. The control sample (1ng OT/ml) shows an intensity of 1300 cps at tr 
1.47 min for the OT peak (figure 4). Figure 5 and 6 show the result for the sample-prepared 
plasma sample (1ng/ml) using the MSIATM Protein AG and Protein G pipette tips respectively. 
No OT was detected in either of them.    
 
Figure 4. MSIATM control 1 ng/ml. OT tr 1.47 min. 
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Figure 5. MSIATM Protein AG-pipette tip – plasma sample  1 ng/ml. 
 
Figure 6.  MSIATM Protein G-pipette tip – plasma sample  1 ng/ml. 
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Appendix IV: Variation in QC-areas 
Table 1 shows the variation between QC-areas for duplicate samples when using IS (100 
pg/ml) in the elution. As can be seen there is very small variation between the duplicate 
samples (QC-area 1 & 2) 
Table 1. The variation in QC-areas when using IS (100pg/ml) in the elution. 
 100ul Elution Buffer 2a    
OT conc. 
(pg/ml) 
QC Area 1 QC Area 2 Standard 
Area 
OT QC Area/OT standard Area (%) 
10 64,8 41,2 141,5 37 
25 129,2 124,9 349,6 36 
40 183,5 177,5 533,5 34 
55 264,7 234,6 771,3 32 
70 302,1 295,9 957,5 31 
85 333,9 386,8 1206,4 30 
100 396,5 397,3 1363,7 29 
 150ul Elution Buffer 2a    
OT conc. 
(pg/ml) 
QC Area 1 QC Area 2 Standard 
Area 
OT QC Area/ OT standard Area (%) 
10 40,9 35,6 146,0 26 
25 92,5 79,6 299,5 29 
40 171,9 174,0 423,2 41 
55 226,5 216,3 683,4 32 
70 265,0 251,6 718,3 36 
85 355,9 344,0 963,1 36 
100     
 100ul Elution Buffer 2a + 50uL 0,03% BSA    
OT conc. 
(pg/ml) 
QC Area 1 QC Area 2 Standard 
Area 
OT QC Area/ OT standard Area (%) 
10 51,0 43,2 140,4 34 
25 116,6 115,5 334,5 35 
40 133,3 120,5 457,8 28 
55 208,1 211,6 653,0 32 
70 247,50 287,7 874,6 31 
85 316,4 235,0 978,9 28 
100 358,6 286,3 1265,6 25 
 
